Baseline serum GDF-15 levels have been found to be an independent predictor of adverse outcomes in COPD patients, including accelerated pulmonary function decline, higher yearly exacerbation rates and increased mortality [33]. Here, GDF15 is linked to chronic obstructive pulmonary disease.